206 related articles for article (PubMed ID: 26253281)
21. Sarcoma Risk in Uterine Surgery in a Tertiary University Hospital in Germany.
Kundu S; Zachen M; Hertel H; Hillemanns P; Soergel P
Int J Gynecol Cancer; 2017 Jun; 27(5):961-966. PubMed ID: 28498262
[TBL] [Abstract][Full Text] [Related]
22. Technique for Tissue Containment and Extraction in the Complex Minimally Invasive Myomectomy Setting.
Moawad GN; Tyan P; Awad C
J Minim Invasive Gynecol; 2019; 26(5):809-810. PubMed ID: 30315895
[TBL] [Abstract][Full Text] [Related]
23. Incidental power morcellation of malignancy: a retrospective cohort study.
Graebe K; Garcia-Soto A; Aziz M; Valarezo V; Heller PB; Tchabo N; Tobias DH; Salamon C; Ramieri J; Dise C; Slomovitz BM
Gynecol Oncol; 2015 Feb; 136(2):274-7. PubMed ID: 25740603
[TBL] [Abstract][Full Text] [Related]
24. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
Raspagliesi F; Maltese G; Bogani G; Fucà G; Lepori S; De Iaco P; Perrone M; Scambia G; Cormio G; Bogliolo S; Bergamini A; Bifulco G; Casali PG; Lorusso D
Gynecol Oncol; 2017 Jan; 144(1):90-95. PubMed ID: 27817933
[TBL] [Abstract][Full Text] [Related]
25. Uterine sarcomas and parasitic myomas after laparoscopic hysterectomy with power morcellation.
Tan-Kim J; Hartzell KA; Reinsch CS; O'Day CH; Kennedy JS; Menefee SA; Harrison TA
Am J Obstet Gynecol; 2015 May; 212(5):594.e1-10. PubMed ID: 25499259
[TBL] [Abstract][Full Text] [Related]
26. Impact of Surgery on the Evolution of Uterine Sarcomas.
Cusidó M; Fargas F; Baulies S; Plana A; Rodríguez I; Tresserra F; Pascual MA; Fábregas R
J Minim Invasive Gynecol; 2015; 22(6):1068-74. PubMed ID: 26070730
[TBL] [Abstract][Full Text] [Related]
27. Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB; Handal-Orefice R; Hanchate AD; Lin M; Paasche-Orlow MK
Womens Health Issues; 2016; 26(1):21-6. PubMed ID: 26701205
[TBL] [Abstract][Full Text] [Related]
28. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
Pedra Nobre S; Hensley ML; So M; Zhou QC; Iasonos A; Leitao MM; Ducie J; Chiang S; Mueller JJ; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2021 Jan; 160(1):99-105. PubMed ID: 33158511
[TBL] [Abstract][Full Text] [Related]
29. Medical Device Safety and Surgical Dissemination of Unrecognized Uterine Malignancy: Morcellation in Minimally Invasive Gynecologic Surgery.
Hall T; Lee SI; Boruta DM; Goodman A
Oncologist; 2015 Nov; 20(11):1274-82. PubMed ID: 26382742
[TBL] [Abstract][Full Text] [Related]
30. Laparoscopic Myomectomy: A Single-center Retrospective Review of 514 Patients.
Bean EM; Cutner A; Holland T; Vashisht A; Jurkovic D; Saridogan E
J Minim Invasive Gynecol; 2017; 24(3):485-493. PubMed ID: 28104498
[TBL] [Abstract][Full Text] [Related]
31. Predictors of leiomyoma recurrence after laparoscopic myomectomy.
Yoo EH; Lee PI; Huh CY; Kim DH; Lee BS; Lee JK; Kim D
J Minim Invasive Gynecol; 2007; 14(6):690-7. PubMed ID: 17980328
[TBL] [Abstract][Full Text] [Related]
32. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics.
Cho HY; Kim K; Kim YB; No JH
J Obstet Gynaecol Res; 2016 Mar; 42(3):313-8. PubMed ID: 26695124
[TBL] [Abstract][Full Text] [Related]
33. Incidence of occult uterine sarcoma and other unexpected pathologies in patients having surgery for presumed myomas: A retrospective observational study.
Mühlenbrock MV; Navarrete-Rey P; Kovoor E; Guzman-Rojas R; Troncoso F; Miranda-Mendoza I
J Gynecol Obstet Hum Reprod; 2021 Sep; 50(7):101992. PubMed ID: 33217603
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Morcellation Techniques at the Time of Laparoscopic Hysterectomy and Myomectomy.
Meurs EAIM; Brito LG; Ajao MO; Goggins ER; Vitonis AF; Einarsson JI; Cohen SL
J Minim Invasive Gynecol; 2017; 24(5):843-849. PubMed ID: 28483536
[TBL] [Abstract][Full Text] [Related]
35. Laparoscopic hysterectomy with morcellation vs abdominal hysterectomy for presumed fibroids: an updated decision analysis following the 2014 Food and Drug Administration safety communications.
Siedhoff MT; Doll KM; Clarke-Pearson DL; Rutstein SE
Am J Obstet Gynecol; 2017 Mar; 216(3):259.e1-259.e6. PubMed ID: 27890646
[TBL] [Abstract][Full Text] [Related]
36. Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study.
Skorstad M; Kent A; Lieng M
Acta Obstet Gynecol Scand; 2016 Sep; 95(9):984-90. PubMed ID: 27223683
[TBL] [Abstract][Full Text] [Related]
37. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.
Parker WH; Fu YS; Berek JS
Obstet Gynecol; 1994 Mar; 83(3):414-8. PubMed ID: 8127535
[TBL] [Abstract][Full Text] [Related]
38. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
39. Reducing the spread of occult uterine sarcoma at the time of minimally invasive gynecologic surgery.
Wong M; De Wilde RL; Isaacson K
Arch Gynecol Obstet; 2018 Feb; 297(2):285-293. PubMed ID: 29128980
[TBL] [Abstract][Full Text] [Related]
40. The Morcellation Debate: The History and the Science.
Adelman MR
Clin Obstet Gynecol; 2015 Dec; 58(4):710-7. PubMed ID: 26512438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
